Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > Press Releases Press Releases 2021 2020 2019 2018 2017 2016 2015 2014 26 November 2021 Crescendo Biologics Wins “Best Established Biotech Company” at the 2021 OBN Awards View PDF 21 October 2021 Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients View PDF 20 October 2021 Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London View PDF 16 September 2021 Crescendo to participate in upcoming investor conferences View PDF 7 July 2021 Crescendo to participate in upcoming investor conferences View PDF 1 June 2021 Crescendo to participate in upcoming investor conferences View PDF 20 May 2021 Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours View PDF 10 May 2021 Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer View PDF 27 April 2021 Crescendo to participate in upcoming investor conferences View PDF 19 April 2021 Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology View PDF 16 April 2021 New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours View PDF 10 December 2020 Crescendo Biologics expands its ongoing collaboration with Takeda View PDF 6 July 2020 Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy View PDF 5 May 2020 Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic View PDF 3 February 2020 Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer View PDF 15 January 2020 Publication in Cancer Research demonstrates Crescendo Biologics’ Humabody® VH therapeutics outperform conventional antibodies in vivo View PDF 25 October 2019 New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic View PDF 16 October 2019 Crescendo Biologics presenting at key industry events during October 2019 View PDF 24 September 2019 Crescendo Biologics reaches fifth milestone in its strategic collaboration with Takeda View PDF 12 September 2019 Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey View PDF 5 September 2019 Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer View PDF 23 July 2019 Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda View PDF 24 June 2019 Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019 View PDF 31 May 2019 Crescendo Biologics announces prestigious academic research collaborationsView PDF 29 May 2019 Crescendo Biologics achieves another milestone in its strategic collaboration with Takeda View PDF 2 May 2019 Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals View PDF 25 April 2019 Crescendo broadens patent protection in US on VH-producing lambda chain KO mice View PDF 4 April 2019 Theodora Harold to be appointed new CEO at Crescendo Biologics View PDF 21 March 2019 Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019 View PDF 3 January 2019 Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda View PDF 5 November 2018 Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody® View PDF 1 November 2018 Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018 View PDF 18 October 2018 Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic View PDF 1 October 2018 Crescendo Biologics shortlisted for Private Financing Deal of the Year at 2018 Scrip Awards View PDF 20 September 2018 Crescendo Biologics shortlisted for Lifestars Awards 2018 View PDF 20 September 2018 Crescendo Biologics shortlisted for Cambridge Independent Science and Technology Awards 2018 View PDF 11 September 2018 Crescendo Biologics strengthens its management with the appointment of Dr Pavel Pisa as Chief Medical Officer View PDF 15 August 2018 Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda View PDF 2 July 2018 Crescendo Biologics appoints clinical development expert, Dr Igor Matushansky, as Non-Executive Director View PDF 18 June 2018 Crescendo Biologics appoints Eva-Lotta Allan as Non-Executive Director View PDF 30 May 2018 Zai Lab and Crescendo Biologics enter exclusive worldwide license agreement for innovative protein therapeutics for inflammatory indications View PDF 30 April 2018 Crescendo Biologics Ltd. raises $70 Million (€57 Million) in Series B Financing View PDF 16 April 2018 Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda View PDF 21 March 2018 Crescendo Biologics appoints Dani Bach as Non-Executive Director View PDF 20 March 2018 Crescendo Biologics to present poster at AACR Annual Meeting 2018, Chicago View PDF 15 March 2018 Crescendo Biologics’ Colette Johnston to present at 11th Annual Proteins & Antibodies Congress, London View PDF 9 March 2018 Crescendo Biologics’ James Legg to present at 4th Annual Crown Bioscience Cambridge Symposium View PDF 9 March 2018 Crescendo Biologics to attend 12th Annual BIO-Europe Spring 2018, Amsterdam View PDF 2 January 2018 Crescendo Biologics to attend 36th Annual J.P. Morgan Healthcare Conference 2018, San Francisco View PDF 8 December 2017 Crescendo Biologics’ Brian McGuinness to present at IBC Antibody Engineering & Therapeutics Conference View PDF 30 November 2017 Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017 View PDF 10 November 2017 Crescendo Biologics’ CEO, Peter Pack to attend Jefferies Healthcare Conference View PDF 10 November 2017 Crescendo Biologics’ CSO to present at Biotech and Money Investival Showcase View PDF 10 November 2017 Crescendo Biologics’ CEO, Peter Pack, to present at 9th Annual PEGS Europe View PDF 1 November 2017 Crescendo Biologics is pleased to announce that it has been shortlisted for ‘Licensing Deal of the Year’ at the Scrip Awards 2017. 16 June 2017 Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards View PDF 14 June 2017 Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer View PDF 12 June 2017 Crescendo Biologics shortlisted for Biotech and Money 2017 Awards View PDF 2 June 2017 Crescendo Biologics to present at BIO International and ICCS in San Diego, US View PDF 9 May 2017 Crescendo Biologics nominated for Mediscience Emerging Star Award View PDF 4 April 2017 Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer View PDF 6 February 2017 Crescendo Biologics’ CEO, Peter Pack to present and participate in panel at Biotech and Money 2017 View PDF 10 January 2017 Crescendo Biologics partners with software-provider, Genedata, on next-generation immuno-oncology and ADC programs. View PDF 18 October 2016 Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer View PDF 10 October 2016 Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m View PDF 28 September 2016 Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics. View PDF 8 February 2016 Key Oncology Data on Humabody® Drug Conjugates. View PDF 2 February 2016 Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property. View PDF 17 November 2015 Crescendo Appoints New Chairman View PDF 14 October 2015 Crescendo Biologics Launches New Strategy & Appoints Dr Peter Pack as CEO View PDF 27 May 2015 Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award: Biomedical Catalyst Award to Support Development of New Therapies to Target Prostate Cancer View PDF 6 January 2015 Crescendo Biologics to Present at Biotech Showcase™ 2015 View PDF 16 December 2014 Crescendo Biologics’ Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors View PDF 3 October 2014 Crescendo Biologics Recognised at OBN Annual Awards Dinner View PDF 3 April 2014 EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics’ Series A Financing View PDF 28 March 2014 Crescendo Biologics Wins Cambridge Business Innovation Award View PDF 17 December 2013 Crescendo Biologics Raises £17.5M ($28M) in Series A Financing View PDF 16 January 2013 Crescendo Biologics Announces the Crescendo Mouse View PDF 5 October 2012 Crescendo Biologics Extends IP Protection for Mouse Knock Out Technology View PDF 8 August 2012 Crescendo Biologics Extends IP Protection for Transgenic Mouse Technology View PDF 22 June 2011 Crescendo Biologics Appoints Matthew Roe as Chief Business Officer View PDF 4 April 2011 Crescendo Biologics' Mouse Knockout Patent Upheld View PDF 5 January 2011 Mike Romanos Appointed as CEO of Crescendo Biologics View PDF 29 September 2010 Crescendo Biologics Announces First ‘Triple Knockout’ Mouse View PDF 8 January 2010 Clive Dix Appointed as Chairman of Crescendo Biologics View PDF 12 October 2009 Crescendo Biologics Raises £4.5 million in Seed Funding Led by Sofinnova Partners View PDF 12 October 2009 Mike Romanos Appointed as CSO of Crescendo Biologics View PDF Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok